dose finding study of irinotecan for UGT1A1 homozygnous group - dose finding study of irinotecan for UGT1A1 homozygnous group

kobe University Hospital and Graduate School of Medicine0 个研究点目标入组 12 人开始时间: 2009年10月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1)History of serious drug allergy 2)Active concomitant malignancy 3)Prior extensively irradiation for abdominal or bowel bone marrow 4)Symptomatic brain metastasis 5)Systemic continual use of steroids 6)Active infection 7)Persistent diarrhea (watery stool) 8)Intestinal obstraction or paralytic ileus 9)Interstitial pneumonia or pulmonary fibrosis 10)Massive pleural, pericardial effusion or asites that required drainage 11)Need to treatment with atazanavir sulfate 12)Uncontrolled diabetes mellitus 13)Heart disease deemed to unacceptable by diagnosis of cardiogram within the previous 28 days before enrollment 14)Psychological disease deemed to unacceptable for inclusion to the study 15)Pregnant or lactating women, couple wishing pregnant or no mind of prevent pregnancy 16)Other concominant medical condition deemed to inadequate for inclusion to the study

发起方

kobe University Hospital and Graduate School of Medicine